Enlivex Ltd.

IPO

Enlivex | Quality Longevity & Prediction Markets Treasury

Public · Ness Ziona, Israel · Founded 2005 · $225.2M raised

Headquarters
Ness Ziona
Employees
11–50
Founded
2005
Business Model
B2B
Total Funding
$225.2M
Last Round
$8.0M Series BSep 2018
Rounds
3
Type
Public

About

Enlivex is a Nasdaq-listed clinical-stage immunotherapy company developing Allocetra™, an off-the-shelf macrophage reprogramming cell therapy targeting inflammatory diseases including age-related knee osteoarthritis. Phase II data demonstrated 72% pain reduction and 109% functional improvement across over 250 patients, addressing a market valued at over $314 billion.

Summary

Enlivex Ltd. is a Biotech company based in Ness Ziona, Israel, founded in 2005. It has raised $225.2M in total across 3 rounds, most recently a $8.0M Series B round in Sep 2018. Investors include KIP Global Pharma Private Equity Fund.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOMar 2019

Sign up to see all 4 rounds

Series B through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Enlivex Ltd. on Indexed.vc
<a href="https://indexed.vc/companies/enlivex-ltd"><img src="https://indexed.vc/api/badge/company/enlivex-ltd" alt="Enlivex Ltd. on Indexed.vc" width="260" height="76" /></a>